source
- Regeneron posts positive phase 2 data for baloncibart in nervous system disorder, eyes pivotal trialRegeneron has posted positive phase 2 data on baloncibart in postural orthostatic tachycardia syndrome, teeing the biotech up to start a potentially pivotal trial in the first half of 2027.
- Local schools launch experiments to curb teen phone addictionA teacher in Milwaukee asked her digital journalism class to write about their relationship with devices, uncovering disturbing accounts of constant phone use and online abuse. The students descri…